Recent advances in micro-sized oxygen carriers inspired by red blood cells

Algae-inspired chitosan-pullulan-based multifunctional hydrogel for enhanced wound healing

Chronic wounds caused by hyperglycaemia, hypoxia and bacterial infections are common complications in diabetic patients and chronic wound repair is extremely challenging in clinical practice. A series of hydrogels QPMP with good antioxidant and antimicrobial functions were prepared based on quaternized chitosan (QCS), oxidized pullulan polysaccharide (OP), dopamine-coated polypyrrole (PPY@PDA), and Chlorella vulgaris. The Schiff base cross-linking between the quaternized chitosan (QCS) and oxidized pullulan polysaccharide (OP) constitutes the basic skeleton of the hydrogel, and imparts a certain antimicrobial ability to the hydrogel. Chlorella vulgaris continuously produced oxygen under light conditions to relieve wound hypoxia and promote wound healing. The incorporation of PPY@PDA gave the hydrogel near-infrared (NIR) irradiation-assisted bactericidal activity and antioxidant activity, and as a conductive hydrogel, the hydrogel can be used to sense wound exudate and temperature changes, which can help to achieve the integration of diagnosis and treatment of wound healing. Most importantly, in a chronic wound model, the QPMP hydrogel was more effective in controlling the level of wound inflammation and promoting collagen deposition, angiogenesis, and early wound closure compared to the HeraDerm dressing. Therefore, this conductive oxygen-producing hydrogel is extremely beneficial for chronic wound healing in diabetes.

Engineering Synthetic Erythrocytes as Next-Generation Blood Substitutes

Blood scarcity is one of the main causes of healthcare disruptions worldwide, with blood shortages occurring at an alarming rate. Over the last decades, blood substitutes has aimed at reinforcing the supply of blood, with several products (e.g., hemoglobin-based oxygen carriers, perfluorocarbons) achieving a limited degree of success. Regardless, there is still no widespread solution to this problem due to persistent challenges in product safety and scalability. In this Review, we describe different advances in the field of blood substitution, particularly in the development of artificial red blood cells, otherwise known as engineered erythrocytes. We categorize the different strategies into natural, synthetic, or hybrid approaches, and discuss their potential in terms of safety and scalability. We identify synthetic engineered erythrocytes as the most powerful approach, and describe erythrocytes from a materials engineering perspective. We review their biological structure and function, as well as explore different methods of assembling a material-based cell. Specifically, we discuss how to recreate size, shape, and deformability through particle fabrication, and how to recreate the functional machinery through synthetic biology and nanotechnology. We conclude by describing the versatile nature of synthetic erythrocytes in medicine and pharmaceuticals and propose specific directions for the field of erythrocyte engineering.

Development of Perfluoro Decalin/Fluorinated Polyimide Core-Shell Microparticles via SPG Membrane Emulsification Using Methyl Perfluoropropyl Ether Cosolvent

Red blood cell-inspired perfluorocarbon-encapsulated core-shell particles have been developed for biomedical applications. Although the use of perfluorodecalin (FDC) is expected for core-shell particles owing to its high oxygen solubility, the low solubility of FDC in any organic solvent, owing to its fluorous properties, prevents its use in core-shell particles. In this study, a new cosolvent system composed of dichloromethane (DCM) and heptafluoropropyl methyl ether (HFPME) was found to dissolve both FDC and fluorinated polyimide (FPI) based on a systematic study using a phase diagram, achieving a homogeneous disperse phase for emulsification composed of oxygen-permeable FPI and oxygen-soluble FDC. Using this novel cosolvent system and Shirasu porous glass (SPG) membrane emulsification, FDC-encapsulated FPI shell microparticles were successfully prepared for the first time. In addition to oxygenation, demonstrated using hypoxia-responsive HeLa cells, the fabricated core-shell microparticles exhibited monodispersity, excellent stability, biocompatibility, and oxygen capacity.

The Application of Drugs and Nano-Therapies Targeting Immune Cells in Hypoxic Inflammation

Immune cells are pivotal in the dynamic interplay between hypoxia and inflammation. During hypoxic conditions, HIF-1α, a crucial transcription factor, facilitates the adaptation of immune cells to the hypoxic micro-environment. This adaptation includes regulating immune cell metabolism, significantly impacting inflammation development. Strategies for anti-inflammatory and hypoxic relief have been proposed, aiming to disrupt the hypoxia-inflammation nexus. Research extensively focuses on anti-inflammatory agents and materials that target immune cells. These primarily mitigate hypoxic inflammation by encouraging M2-macrophage polarization, restraining neutrophil proliferation and infiltration, and maintaining Treg/TH17 balance. Additionally, oxygen-releasing nano-materials play a significant role. By alleviating hypoxia and clearing reactive oxygen species (ROS), these nano-materials indirectly influence immune cell functions. This paper delves into the response of immune cells under hypoxic conditions and the resultant effects on inflammation. It provides a comprehensive overview of various therapies targeting specific immune cells for anti-inflammatory purposes and explores nano-materials that either carry or generate oxygen to alleviate anoxic micro-environments.